DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20222133
Published: 2022-08-24

Is pregabalin better than gabapentin in treatment of neuropathic pain? An observation-based study at tertiary care centre of North India

Mohit Shukla, Rakesh Chandra Chaurasia, Dwividendra Kumar Nim, Kamlesh Kumar Sonkar

Abstract


Background: The present study was undertaken to assess the efficacy of pregabalin and gabapentin in treatment of neuropathic pain at a government tertiary care hospital of Uttar Pradesh, India. Due to indiscriminate use of drugs for treatment of neuropathic pain, selection of an effective drug is need of hour.

Methods: Out of 130 patients, 62 patients were given pregabalin and 68 were given gabapentin. Douleur Neuropathique 4 questionnaire (DN4) which was used to diagnose patients of neuropathic pain. Efficacy of drug was based on their capability to decrease neuropathic pain at regular intervals.

Results: On comparing the efficacy of drugs by their ability to decrease neuropathic pain, there was a significant difference when comparing pregabalin and gabapentin, pregabalin being statistically significant than gabapentin.

Conclusions: On the basis present study efficacy of pregabalin 300 mg once daily brought better improvement of symptoms and sign than that of gabapentin 600 mg administered once daily dose. So pregabalin is a better drug than gabapentin.


Keywords


Nociception, Questionnaires, Neurotransmitters, Anticonvulsant

Full Text:

PDF

References


Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9): 1976-82.

Johnson P, Becker L, Halpern R, Sweeney M. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013; 33(1):35-44.

Mu A, Weinberg E, Moulin DE. Pharmacological management of chronic neuropathic pain, review of the Canadian pain society consensus statement. Can Fam Physician. 2017(63):844-52.

Debono DJ, Hoeksema LJ, Hobbs RD. Caring for patients with chronic pain: pearls and pitfalls. J Am Osteopath Assoc. 2013;113(8):620-7.

Turk DC, Dworkin RH. What should be the core outcomes in chronic pain clinical trials?. Arth Res Ther. 2004;6(4):151-4.

Hobbs RD. Classification of chronic pain descriptions of chronic pain syndromes and definitions of pain terms. IASP. 2002;2:212-8.

Van HO, Austin SK, Khan RA, Smith BH. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain. 2014;155:654-62.

Pharmacological NNpia, management in non-specialist settings. Available at: https://nice.org.uk/ CGAaguidance/cg173. Accessed on 20 October 2021.

Finnerup NB, Attal N, Haroutounian S. Pharmacotherapy for neuropathic pain in adults: Asystematic review and meta-analysis and updated NeuPSIG recommendations. Lancet Neurol. 2015; 14(2):162-73.

Sumitani M, Sakai T, Matsuda Y. Executive summary of the clinical guidelines of pharmacologic therapy for neuropathic pain. J Anesth. 2018;32(3):463-78.

Attal N, Cruccu G, Baron R. EFNS guidelines on the pharmacological treatment of neuro pathic pain. Eur J Neurol. 2010;17:67-88.

Mu A, Weinberg E, Moulin wE, Clarke H. Pharmacologic management of chronic neuropathic pain review of the Canadian pain society consensus statement. 2017;5:63.

Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.

Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3):S3-14.

Pan B, Yu H, Park J, Yu YP, Luo ZD, Hogan QH. Painful nerve injury upregulates thrombospondin-4 expression in dorsal root ganglia. J Neurosci Res. 2015;93(3):443-53.

Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian pain society. Pain Res Manage. 2007;12(1):13-21.

Casale R, Symeonidou Z, Bartolo M. Topical treatments for localized neuropathic pain. Curr Pain Headache Rep. 2017;21(3):15.

Bates D, Schultheis BC, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019;20(1): S2-12.

Van Seventer R, Feister HA, Young JP, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opinion. 2006; 22(2):375-84.

Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6(4):253-60.

Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.

Gudala K, Ghai B, Bansal D. Hindi version of short form of douleur neuropathique 4 (S-DN4) questionnaire for assessment of neuropathic pain component: a cross-cultural validation study. Korean J Pain. 2017;30(3):197-206.

Haussleiter IS, Richter H, Scherens A, Schwenkreis P, Tegenthoff M. NeuroQuick–a novel bedside test for small fiber neuropathy?. Eur J Pain. 2008;12:1000-7.

Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, et al. Using screening tools to identify neuropathic pain. Pain. 2007;127:199-203.

Attal N, Mazaltarine G, Perrouin-Verbe B, Albert T. Chronic neuropathic pain management in spinal cord injury patients. What is the efficacy of pharmacological treatments with a general mode of administration? (oral, transdermal, intravenous). Ann Physical Rehab Med. 2009;52(2):124-41.

Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hospice Palliative Care. 2012; 29(3):177-82.

Kiss G. Drug therapy of neuropathic pain based on the latest recommendations. Ideggyogyaszati Szemle. 2015;68(3-4):93-8.

Robertson K, Marshman LA, Plummer D. Pregabalin and gabapentin for the treatment of sciatica. J Clin Neurosci. 2016;26:1-7.

Wang BC, Liu D, Furnback WE, Bifa F, Dong P, Xie L, et al. The cost-effectiveness of pregabalin versus gabapentin for peripheral neuropathic pain (pNeP) and Postherpetic Neuralgia (PHN) in China. Pain Ther. 2016;5(1):81-91.

Markman JD, Jensen TS, Semel D, Li C, Parsons B, Behar R, et al. Effects of pregabalin in patients with neuropathic pain previously treated with gabapentin: a pooled analysis of parallel-group, randomized, placebo-controlled clinical trials. Pain Prac. 2017; 17(6):718-28.

Robertson K, Marshman LAG, Hennessy M, Harriss L, Plummer D. Pregabalin versus gabapentin in the treatment of sciatica: study protocol for a randomised, double-blind, cross-over trial (PAGPROS). Trials. 2018;19(1):21.

Kopel J, Brower GL. Effectiveness of pregabalin as a secondary treatment for neuropathic pain from postherpetic neuralgia. Baylor Univ Medical J. 2020; 33(3):469-70.

Tong C, Zhengyao Z, Mei L, Dongpo S, Qian H, Fengqun M. Pregabalin and gabapentin in patients with spinal cord injury-related neuropathic pain: a network meta-analysis. Pain Ther. 2021;10(2):1497-509.